The purpose of the study is to evaluate how long the disease remains controlled after receiving the drug. Participants will receive a series of intravenous infusions of the medication, with each infusion given a few weeks apart. Throughout the trial, blood tests will measure PSA (a protein that indicates prostate cancer activity), and imaging scans such as a special scan that shows PSMA activity (PSMA PET/CT) and a scan that measures radiation dose to the tumor (SPECT/CT) will be performed to track tumor changes. Standard imaging criteria (RECIST) are used to assess whether tumors shrink, stay the same, or grow.

After the treatment phase, patients are followed for several months with regular check‑ups, blood tests, and scans to monitor disease status, side effects, pain levels, and overall well‑being. The study records how long patients live without the disease getting worse, as well as any improvements in symptoms or quality of life.

The purpose of the study is to determine whether the fosfomycin regimen works at least as well as the usual antibiotics. Participants are randomly assigned to receive either the fosfomycin combination or one of the standard treatments for about twelve days. After finishing the medication, they are checked several times over the next few weeks to see if the fever has resolved, symptoms have disappeared, and no additional antibiotics are needed.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

The purpose of the study is to evaluate how well the PSMA PET/CT scan can detect cancer recurrence one year after HIFU treatment. Participants will have the imaging tests at the one‑year follow‑up, and any suspicious areas will be checked with a biopsy, which serves as the reference standard. The results will be collected to determine the accuracy of the imaging methods.

The aim is to see whether treatment can lower the need for a repeat prostate biopsy by reducing prostate inflammation and related markers. Participants will be randomly assigned to receive either the active capsule or an inert matching capsule (placebo) for about one year, with regular check‑ups.

During the study, men will take one capsule each day and attend clinic visits where blood will be drawn to measure PSA (a protein that can indicate prostate activity), and imaging with MRI will be performed to assess the PIRADS score, a system that rates how likely a lesion is to be cancer. They will also complete questionnaires such as the IPSS (which rates urinary symptoms) and the IIEF-5 (which assesses erectile function). The study will track whether a repeat biopsy is needed and any changes in these measurements over the 12‑month period.

The purpose of the study is to explore whether this treatment switch can improve the PSA response in this setting. In the study, participants first receive the standard hormone-based treatment, and then treatment is changed to BMS-986365. The study then follows how the cancer and symptoms change over time, while also checking for side effects, blood test changes, and heart tracing changes. The study also looks at general health and pain over the course of treatment.

The purpose of the study is to determine whether a shorter, 7‑day course of the antibiotic works as well as the standard 14‑day course in achieving a cure of the infection.

Participants are randomly assigned to receive either the short or the longer treatment. After finishing the medication, they are followed up with visits about two weeks and four weeks later to check whether symptoms have resolved, whether the infection has returned, and whether any side effects have occurred. “Clinical cure” means the patient’s signs and symptoms have returned to normal and no additional antibiotics are needed.

The main aim of the trial is to find out whether either medication can lower the risk of developing new kidney stones and slow the progression of the disease. Participants will be followed for up to two years, with regular clinic visits where blood and urine samples are taken and simple imaging scans are performed to look for stones and assess kidney health. One of the key laboratory measures is the eGFR, which estimates how well the kidneys are filtering waste from the blood.

During the study, researchers will compare the occurrence of kidney stones, changes in kidney function, and overall physical and mental well‑being between the groups receiving the study medicines and those receiving a placebo. The information gathered will help determine if these treatments are useful for preventing stone formation and preserving kidney health in people with this condition.

Participants will take leflutrozole in the form of an oral capsule. During the study, various biological markers will be monitored, including hormones in the blood and semen, such as testosterone and follicle-stimulating hormone. Additionally, changes in certain substances in the blood, urine, and semen, as well as body mass index and blood sugar levels, may be tracked over the course of the treatment.

Participants in the study will receive either the standard amount of abiraterone acetate or a dose that is customized based on regular blood tests. These blood tests help determine the Cmin, which refers to the lowest concentration of the drug found in the blood between doses. By monitoring these levels, doctors can see if adjusting the amount of medicine improves the time during which the cancer does not appear to grow on imaging tests, a measurement known as radiographic progression-free survival. Throughout the study, various factors such as prostate-specific antigen (a protein often used to track prostate cancer activity) and overall health will be observed.

The study is divided into different parts to closely monitor how the body reacts to the treatment. One part of the research looks at how the medication is processed by the body and determines the maximum tolerated dose, which is the highest amount of a drug that can be given without causing unacceptable side effects. Another part of the study examines the preliminary ability of AZD9750 to shrink tumors or reduce the levels of PSA, a protein used to track prostate cancer activity.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

During the course of the study, participants will receive the study drug to monitor how the body reacts to it. Researchers will observe the effects of ADX-038 over time, specifically looking for any side effects or changes in the amount of protein released in the urine, which is often measured through a UPCR (urine protein-to-creatinine ratio) test. This test helps in understanding how well the kidneys are functioning.

One of the treatments being tested is lutetium (177lu) vipivotide tetraxetan, which is administered as a solution for injection or infusion directly into a vein. This medication is a type of radiopharmaceutical, meaning it contains a small amount of radiation designed to target cancer cells. The study follows a specific design to compare different treatment approaches against standard care to see which options are most effective for patients.

The purpose of the study is to evaluate how well a rectal treatment works for these symptoms. Participants will be assigned to receive either budesonide, which is a type of steroid medication, or a placebo. Both medications will be administered as a suppository, which is a small, solid medicated piece inserted into the rectum for absorption. The study will take place over eight weeks, with the medication used once every day.

Participants will receive dexamethasone at different times during the study to measure how much of the medicine stays in the blood. The first measurement will be taken before starting the antihormonal therapy, and then again after the body has adjusted to the regular use of enzalutamide or apalutamide. Blood samples will be collected to measure the amount of dexamethasone present over time, which helps researchers understand if the antihormonal medicines are affecting how the body breaks down the glucocorticoid. Later in the study, participants may receive a higher dose of dexamethasone to see if increasing the amount can make up for any changes caused by the antihormonal treatment.

The study will also look at whether any unwanted effects occur when dexamethasone is given on three separate occasions during the treatment period. Researchers want to understand if the combination of these medicines requires any adjustments to dosing to ensure patients receive the full benefit of their corticosteroid treatment while taking their cancer therapy. The information gathered will help doctors better understand how these medicines interact in the body and whether treatment plans need to be modified when these medications are used together.

The purpose of this study is to find out if giving the antibiotic for a shorter period of time works just as well as the usual longer treatment. Specifically, the study will compare giving the antibiotic for 24 hours after the fever goes away versus giving it for the standard 10 days. The study will check if the shorter treatment is as good as the longer treatment by looking at whether the infection comes back within 30 days after stopping the antibiotic. An infection coming back means that signs and symptoms of the urinary tract infection with fever appear again and tests confirm the presence of bacteria in the urine.

During the study, children will be randomly assigned to receive either the shorter or the standard length of antibiotic treatment. The maximum daily amount of the medication that can be given is 3 grams, and the maximum total amount over the entire treatment period is 30 grams. After treatment ends, children will be monitored through follow-up visits where doctors will check for any signs that the infection has returned. The study will also look at how well the treatment works in the short term and whether bacteria that are resistant to the antibiotic appear after treatment.

During the study, patients will undergo PSMA PET/CT scans, which are special imaging tests that combine two types of scans to find and measure prostate cancer in the body. These scans will be done before starting the treatment and again after taking darolutamide to compare the results. The study will look at whether the number of cancer deposits increases, whether existing cancer spots show higher levels of the PSMA protein, or whether the cancer spots become larger or more visible after treatment with darolutamide. This effect, where the visibility of cancer temporarily increases after starting certain hormone-blocking treatments, is sometimes called a flare phenomenon.

Patients participating in this study will have already received previous treatment for their prostate cancer, either surgery to remove the prostate or radiation therapy, and their scans will show between one and five areas where the cancer has spread to bones or lymph nodes. The study will also collect information about any side effects that occur and how patients feel during the treatment by using quality of life questionnaires. The measurements taken during the scans will include the number of cancer spots, their size, their location in the body, and a measurement called SUVmax which indicates how much the PSMA protein is present in each spot.

The purpose of the study is first to find the right dose of izalontamab brengitecan to use, and then to see how well this medicine works compared to platinum-based chemotherapy in people whose cancer has gotten worse during or after treatment with immunotherapy. The study is designed for people who have already received immunotherapy treatment and whose cancer has continued to grow or spread despite this treatment. Participants in this study must be able to receive platinum-based chemotherapy and should not have had more than two previous types of treatment for their cancer that has spread.

The study will be done in two phases. In the first phase, researchers will determine the best dose of izalontamab brengitecan by looking at how safe it is and how well it works. In the second phase, participants will be randomly assigned to receive either izalontamab brengitecan or platinum-based chemotherapy, and the two treatments will be compared. The study will measure how long it takes for the cancer to get worse, how long participants live, how many people respond to treatment, and how long those responses last. The study will also look at how the treatments affect quality of life.

During the study, participants will use the diagnostic tool to help them determine if it is safe for them to take the medication. The study will look at how well participants follow the prescribed way of taking the medicine, whether the medication is effective in allowing them to achieve and maintain an erection sufficient for sexual intercourse, and how many sexual encounters are satisfactory after taking the medication. The study will also monitor any unwanted effects that may occur during the treatment period, which can last up to 42 days.

This is a multicenter study, meaning it will take place at several different locations. Participants will be adult men who are sexually active and planning to have sexual interactions. Throughout the study, information will be collected about how participants use the medication and their experiences with it to understand if they can safely manage their treatment independently.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

Patients in this study will receive both medications over a period of up to 24 months. The study will measure how many patients have their tumors shrink or disappear completely after receiving this treatment combination. Doctors will use imaging scans to check the size of the tumors and determine whether the treatment is working. The study will also track how long patients live, how long the cancer stays under control without getting worse, and how long any positive response to the treatment lasts. Additionally, the study will monitor how long patients can maintain a response where their cancer is either shrinking, disappearing, or staying stable.

Throughout the study, doctors will carefully watch for any side effects or unwanted reactions that patients may experience from the medications. The severity of these side effects will be recorded and graded according to a standard system used in cancer research. The study will also ask patients questions about their quality of life to understand how the treatment affects their daily activities and overall well-being. Patients will need to have tumor tissue samples available for testing, and they must have measurable disease that can be tracked on scans. The study requires patients to be healthy enough to participate, with adequate blood cell counts, liver function, and kidney function.

The purpose of this study is to determine if combining these chemotherapy drugs with precisely targeted radiation therapy (called stereotactic ablative radiotherapy) can help control cancer that has spread to a limited number of locations in the body. The treatment involves receiving chemotherapy through an intravenous infusion, along with radiation therapy directed at specific tumor sites identified through specialized imaging scans.

This is a two-phase study where doctors first evaluate the safety of this treatment combination, and then assess how well it works at controlling the cancer. The study is designed for patients who have already tried other standard treatments and have limited remaining treatment options. The treatment approach aims to target both widespread disease with chemotherapy and specific tumor sites with focused radiation therapy.

The purpose of this research is to determine if this treatment is both safe and effective for patients with this specific type of kidney cancer. During the study, participants will receive the medication directly into their renal pelvis (the part of the kidney that collects urine). The treatment will be monitored over time to see how well it works in treating the cancer.

This is a single-arm, open-label study, which means all participants will receive the same treatment, and there is no comparison group. The study will track how patients respond to the treatment over an extended period, with particular attention paid to any changes in their cancer status and any side effects that may occur. Participants will be followed for at least 18 months after receiving their first dose of the medication.

The purpose of this research is to determine how safe and effective these treatment combinations are for patients whose bladder cancer has not responded to standard therapy. The treatment involves placing medication directly into the bladder through a process called intravesical instillation. The study will monitor how well the cancer responds to these treatments over time.

During the study, which may last up to 24 months, participants will receive their assigned treatment according to a specific schedule. Some patients will receive only nadofaragene firadenovec, while others will receive it in combination with either chemotherapy or immunotherapy. The study will track whether the cancer disappears completely after treatment, which is called a complete response.

The trial is a first-in-human study, meaning this treatment has not been tested in people before. It involves taking a sample of the patient’s tumor tissue through surgery, extracting the tumor-infiltrating lymphocytes, growing them in a laboratory to increase their numbers, and then returning these cells to the patient as a form of treatment. Patients will receive multiple administrations of the CC-38 treatment over the course of the study.

To participate, patients must have colorectal cancer that has spread to other parts of the body (stage IV) or prostate cancer that is either locally advanced (stage III) or has spread to other parts of the body (stage IV). Their disease must have progressed despite previous standard treatments, and they must have measurable disease remaining after the tumor sample is taken for creating the treatment.

The investigation is designed as a randomized, double-blind, placebo-controlled study, which means some participants will receive the actual medication while others will receive a placebo, with neither the participants nor the researchers knowing who receives which treatment during the study. Researchers will monitor changes in the number of wet nights per week, measure the amount of urine produced at night, assess bladder capacity, and track any side effects that may occur.

The purpose of this study is to determine if the combination of darolutamide with bipolar androgen therapy improves how long patients live without their cancer progressing and their quality of life compared to the current standard treatment. Participants will be randomly assigned to receive either the experimental treatment combination or the standard care, while continuing their androgen deprivation therapy throughout the study.

Clinical trial information for patient recruitment must be carefully reviewed by ethics committees and regulatory bodies to ensure it’s accurate, balanced, and not misleading. Creating such content outside official channels could potentially:

1. Provide misleading medical information
2. Circumvent regulatory oversight designed to protect patients
3. Be used in ways that don’t align with proper informed consent processes

If you need assistance with clinical trial descriptions, I’d recommend working directly with your institution’s IRB or ethics committee, clinical research office, or regulatory affairs department who can provide appropriate guidance.

Participants in this study will undergo robot-assisted laparoscopic prostatectomy (a minimally invasive surgical procedure to remove the prostate) with extended pelvic lymph node dissection (removal of lymph nodes from the pelvic area). Before surgery, patients will receive an injection of the 99mTc-hPSMA tracer. During the operation, the surgeon will use special instruments to detect both the radioactive and fluorescent signals from the tracer, which should concentrate in cancerous areas. This may help the surgeon to better identify and remove all cancer tissue while preserving healthy tissue.

The study will evaluate how well the tracer works for identifying cancer in the prostate and lymph nodes, comparing what is seen during surgery with the results of laboratory examination of the removed tissue. It will also track any side effects from the tracer for 14 days after injection and measure PSA (prostate specific antigen, a blood test marker for prostate cancer) levels after surgery to assess outcomes.

The purpose of this study is to evaluate the safety of PolyCore in patients who are starting peritoneal dialysis. The study will monitor participants for any side effects and changes in their health. Participants will receive the PolyCore solution through a process called intraperitoneal use, which means it is administered into the abdominal cavity. The study will involve regular check-ups where doctors will examine the participants, check their vital signs, and perform blood tests to ensure their safety.

Throughout the study, participants will have their kidney function and overall health closely monitored. This includes regular assessments of their blood chemistry, body weight, and the effectiveness of the dialysis treatment. The study aims to gather information on how well PolyCore works and how safe it is for people with End-Stage Kidney Disease who are undergoing peritoneal dialysis. The trial is expected to continue until 2027, providing valuable insights into the treatment of this serious condition.

The purpose of the study is to determine which approach is more effective in helping men achieve good unassisted erections 24 months after surgery. Participants will be followed for a total of 24 months, with regular check-ins to monitor their progress. The study will also look at other aspects of sexual health and quality of life, such as orgasmic function, feelings of masculinity, and the impact on partners. The trial will include the use of questionnaires to gather information on these topics.

In addition to sildenafil, another treatment option being studied is Androskat, which is a solution for injection containing two active substances: phentolamine mesilate and papaverine hydrochloride. This treatment is administered through an injection directly into the penis. The study will compare the effectiveness and side effects of these treatments to determine the best approach for penile rehabilitation after prostate cancer surgery.

In this study, the medications being used include ALFATIL, which contains the active substance cefaclor, Bactrim, which contains sulfamethoxazole and trimethoprim, and AUGMENTIN, which contains amoxicillin and clavulanic acid. These medications are all antibiotics, which are drugs used to treat bacterial infections. The trial will compare the effects of circumcision alone, circumcision with antibiotics, and antibiotics alone on the risk of fUTIs.

The study will follow participants over a two-year period to observe the time it takes for the first fUTI to occur, if at all. It will also look at the number of infections, any changes in kidney health, and the types of bacteria causing the infections. The goal is to determine the best approach to reduce the risk of fUTIs in boys with PUV, using historical data to enrich the findings. Participants will be monitored for their adherence to the antibiotic treatments and the overall effectiveness of the different approaches will be assessed.

In addition to darolutamide, the study will involve other treatments that are commonly used for mCRPC. These include Cabazitaxel, a chemotherapy drug given as an infusion; Xofigo, a radioactive injection used to treat cancer that has spread to the bones; Docetaxel, another chemotherapy infusion; Lynparza, a tablet that targets cancer cells with specific genetic changes; and Lutathera, a radioactive infusion used for certain types of tumors. The purpose of the study is to assess how well darolutamide, when added to these treatments, can help delay the progression of the cancer as seen on imaging tests.

Participants in the study will receive either the standard treatment alone or the standard treatment plus darolutamide. The study will monitor how long it takes for the cancer to progress, as well as overall survival and other health outcomes. The trial is designed to provide valuable information on whether adding darolutamide can improve outcomes for patients with mCRPC. The study is expected to continue until 2030, with recruitment starting in 2025.

The study will observe how well these methods help in removing the bladder tumor completely and whether there is any remaining cancer or changes in the cancer stage when the procedure is repeated. Participants will be randomly assigned to either the PDD or WL group. The study will also look at the recurrence of cancer three months after the procedure, the quality of life of participants, and any side effects experienced. Quality of life will be assessed using specific questionnaires designed for bladder cancer patients.

The trial aims to provide valuable information on the effectiveness of using PDD compared to WL during TURB for patients with NMIBC. This could potentially lead to better treatment outcomes and improved quality of life for patients with this type of bladder cancer. The study is expected to continue until 2028, with recruitment starting in 2025.

The purpose of the study is to compare two approaches to hormone therapy: intermittent maximum androgen blockade (iMAB) and continuous maximum androgen blockade (cMAB). The study aims to determine the benefits and risks of these approaches in patients who have shown a significant response to initial hormone therapy. Participants will be randomly assigned to either continue their hormone therapy without interruption or to have breaks in their treatment. The study will monitor how long patients can go without restarting hormone therapy and compare the overall survival rates between the two groups.

Throughout the study, participants will be observed for changes in their quality of life, including physical functioning, sexual activity, and pain levels. The study will also track the time it takes for patients to need additional prostate cancer treatments and monitor their testosterone and PSA (prostate-specific antigen) levels. The trial will help determine if taking breaks in hormone therapy can maintain the same level of cancer control as continuous treatment while potentially improving the quality of life for patients.

Participants in the study will receive difelikefalin through an intravenous injection, which means the medication is delivered directly into a vein. The study will monitor the participants over a period to observe any side effects and to measure the levels of the medication in their blood. This will help determine how well the medication is tolerated by the body and how it behaves in the bloodstream.

The study is designed to ensure that the medication is safe for use in this specific group of patients. By participating, researchers aim to gather important information that could lead to better treatment options for adolescents suffering from itching related to long-term kidney disease. The study will continue until the estimated end date in 2029, allowing ample time to collect and analyze the data.

The purpose of the study is to see if nadofaragene firadenovec can help prevent the cancer from coming back or getting worse. Participants in the study will receive the treatment every three months. The study will last for up to 24 months, during which time the health of the participants will be closely monitored. The main focus is on how long patients remain free from cancer recurrence, progression, or any cause of death during the study period.

Participants in the study will have already undergone a procedure called transurethral resection of the bladder tumor (TURBT), which is a common method for removing bladder tumors. The study will help determine if adding nadofaragene firadenovec to the treatment plan can improve outcomes for patients with intermediate risk NMIBC. The results of this study could provide valuable information on the potential benefits of this new treatment option for bladder cancer patients.